1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)

Primary Author / Presenter(s)

TW

Tingyu Wang, MD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)

Co-Author(s)

Yuting Yan, PhD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
YY

Ying Yu, PhD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
WX

Wenjie Xiong, MD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, China (People's Republic)
RL

Rui Lv

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, China (People's Republic)
TY

Tengteng Yu, PhD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
WL

Wei Liu

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, China (People's Republic)
YX

Yan Xu

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, China (People's Republic)
WS

Weiwei Sui

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
WH

Wenyang Huang

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
SZ

Shuaishuai Zhang

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
QW

Qi Wang

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, China (People's Republic)
Lugui Qiu, PhD

Professor & Director, Department of Lymphoma & Myeloma
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)
SY

Shuhua Yi, PhD

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
Tianjin, Tianjin, China (People's Republic)